Novo Nordisk’s Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Triggering global regulatory submissions this year for the treatment of obesity
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Subscribe To Our Newsletter & Stay Updated